Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases

Fangke Zhang; Yawei Du; Jiancheng Zheng; Zhengwei Cai; Tao Ding; Pengzhen Zhuang; Ding Yang; Fangling Liao; Yu Zhang; Wu Yang; Yafang Xiao; Weiling He; Wenguo Cui; Weisheng Guo

doi:10.1002/adfm.202211644

Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases

Fangke Zhang
, Yawei Du
, Jiancheng Zheng
, Zhengwei Cai
, Tao Ding
, Pengzhen Zhuang
, Ding Yang
, Fangling Liao
, Yu Zhang
, Wu Yang
, Yafang Xiao
, Weiling He^*
, Wenguo Cui^*
, Weisheng Guo^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

38 Citations (Scopus)

Abstract

Methotrexate (MTX) by oral taking has been employed as the first-line medication for various chronic inflammatory diseases treatment, such as Crohn's disease and rheumatoid arthritis (RA). However, the oral administration of MTX has very limited clinical benefits and will be discontinued due to the suboptimal response and severe adverse effects on intestinal mucosa. Herein, a multistage albumin nanomedicine depot (denoted as MAND) is formulated by encapsulating MTX-loaded human serum albumin nanoparticles (MTX@HSA NPs) into calcium alginate chitosan microcapsules using a gas-shearing technology. The MANDs can provide protection to MTX@HSA NPs with well-persisted biologic activity against gastric acid erosion and realize specific boost release of MTX@HSA NPs in the intestinal tract in response to the mild basic circumstance. The MTX@HSA NPs absorbed by intestine can selectively accumulate in inflammation lesion by exploiting the inflammation targeting ability of HSA. In the animal experiments, the MANDs show improved therapeutic efficacy for the treatment of both RA and colitis with minimized intestinal side effects in respect to the free MTX by oral administration. Therefore, this conceived oral MANDs can promote a more clinic popularity and enhanced benefits of MTX for the treatment of chronic inflammatory diseases.

Original language	English
Article number	2211644
Number of pages	14
Journal	Advanced Functional Materials
Volume	33
Issue number	9
DOIs	https://doi.org/10.1002/adfm.202211644
Publication status	Published - 23 Feb 2023
MoE publication type	A1 Journal article-refereed

Funding

F.Z. and Y.D. contributed equally to this work. The authors thank to Peng Zhang and Wenxiang Chen from Shenzhen Institutes of Advanced Technology (SIAT, CAS) for MH7A cells. This work was supported by grants from National Natural Science Foundation of China (31971302, 22105127, 81871994, 82022037), National Key Research and Development Program of China (2020YFA0908200), Natural Science Foundation of Guangdong Province of China (2019A1515011597, 2019B151502063), the Talent Young Scientist Supporting Program of China Association for Science and Technology, the Educational Commission of Guangdong Province of China key Project (2020ZDZX2001), Guangdong Basic and Applied Basic Research Foundation (2021B1515230009), the joint grant between Guangzhou City and College (202102010106), and Shanghai Pujiang Program (21PJD045). F.Z. and Y.D. contributed equally to this work. The authors thank to Peng Zhang and Wenxiang Chen from Shenzhen Institutes of Advanced Technology (SIAT, CAS) for MH7A cells. This work was supported by grants from National Natural Science Foundation of China (31971302, 22105127, 81871994, 82022037), National Key Research and Development Program of China (2020YFA0908200), Natural Science Foundation of Guangdong Province of China (2019A1515011597, 2019B151502063), the Talent Young Scientist Supporting Program of China Association for Science and Technology, the Educational Commission of Guangdong Province of China key Project (2020ZDZX2001), Guangdong Basic and Applied Basic Research Foundation (2021B1515230009), the joint grant between Guangzhou City and College (202102010106), and Shanghai Pujiang Program (21PJD045).

Keywords

human serum albumin nanomedicines
hydrogel microcapsules
methotrexate
oral administration
rheumatoid arthritis

Access to Document

10.1002/adfm.202211644

Cite this

Zhang, F., Du, Y., Zheng, J., Cai, Z., Ding, T., Zhuang, P., Yang, D., Liao, F., Zhang, Y., Yang, W., Xiao, Y., He, W., Cui, W., & Guo, W. (2023). Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases. Advanced Functional Materials, 33(9), Article 2211644. https://doi.org/10.1002/adfm.202211644

@article{712aa26a2d5a455fb9021a9c0cd0f1a6,

title = "Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases",

abstract = "Methotrexate (MTX) by oral taking has been employed as the first-line medication for various chronic inflammatory diseases treatment, such as Crohn's disease and rheumatoid arthritis (RA). However, the oral administration of MTX has very limited clinical benefits and will be discontinued due to the suboptimal response and severe adverse effects on intestinal mucosa. Herein, a multistage albumin nanomedicine depot (denoted as MAND) is formulated by encapsulating MTX-loaded human serum albumin nanoparticles (MTX@HSA NPs) into calcium alginate chitosan microcapsules using a gas-shearing technology. The MANDs can provide protection to MTX@HSA NPs with well-persisted biologic activity against gastric acid erosion and realize specific boost release of MTX@HSA NPs in the intestinal tract in response to the mild basic circumstance. The MTX@HSA NPs absorbed by intestine can selectively accumulate in inflammation lesion by exploiting the inflammation targeting ability of HSA. In the animal experiments, the MANDs show improved therapeutic efficacy for the treatment of both RA and colitis with minimized intestinal side effects in respect to the free MTX by oral administration. Therefore, this conceived oral MANDs can promote a more clinic popularity and enhanced benefits of MTX for the treatment of chronic inflammatory diseases.",

keywords = "human serum albumin nanomedicines, hydrogel microcapsules, methotrexate, oral administration, rheumatoid arthritis",

author = "Fangke Zhang and Yawei Du and Jiancheng Zheng and Zhengwei Cai and Tao Ding and Pengzhen Zhuang and Ding Yang and Fangling Liao and Yu Zhang and Wu Yang and Yafang Xiao and Weiling He and Wenguo Cui and Weisheng Guo",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley-VCH GmbH.",

year = "2023",

month = feb,

day = "23",

doi = "10.1002/adfm.202211644",

language = "English",

volume = "33",

journal = "Advanced Functional Materials",

issn = "1616-301X",

publisher = "Wiley",

number = "9",

}

TY - JOUR

T1 - Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases

AU - Zhang, Fangke

AU - Du, Yawei

AU - Zheng, Jiancheng

AU - Cai, Zhengwei

AU - Ding, Tao

AU - Zhuang, Pengzhen

AU - Yang, Ding

AU - Liao, Fangling

AU - Zhang, Yu

AU - Yang, Wu

AU - Xiao, Yafang

AU - He, Weiling

AU - Cui, Wenguo

AU - Guo, Weisheng

PY - 2023/2/23

Y1 - 2023/2/23

N2 - Methotrexate (MTX) by oral taking has been employed as the first-line medication for various chronic inflammatory diseases treatment, such as Crohn's disease and rheumatoid arthritis (RA). However, the oral administration of MTX has very limited clinical benefits and will be discontinued due to the suboptimal response and severe adverse effects on intestinal mucosa. Herein, a multistage albumin nanomedicine depot (denoted as MAND) is formulated by encapsulating MTX-loaded human serum albumin nanoparticles (MTX@HSA NPs) into calcium alginate chitosan microcapsules using a gas-shearing technology. The MANDs can provide protection to MTX@HSA NPs with well-persisted biologic activity against gastric acid erosion and realize specific boost release of MTX@HSA NPs in the intestinal tract in response to the mild basic circumstance. The MTX@HSA NPs absorbed by intestine can selectively accumulate in inflammation lesion by exploiting the inflammation targeting ability of HSA. In the animal experiments, the MANDs show improved therapeutic efficacy for the treatment of both RA and colitis with minimized intestinal side effects in respect to the free MTX by oral administration. Therefore, this conceived oral MANDs can promote a more clinic popularity and enhanced benefits of MTX for the treatment of chronic inflammatory diseases.

AB - Methotrexate (MTX) by oral taking has been employed as the first-line medication for various chronic inflammatory diseases treatment, such as Crohn's disease and rheumatoid arthritis (RA). However, the oral administration of MTX has very limited clinical benefits and will be discontinued due to the suboptimal response and severe adverse effects on intestinal mucosa. Herein, a multistage albumin nanomedicine depot (denoted as MAND) is formulated by encapsulating MTX-loaded human serum albumin nanoparticles (MTX@HSA NPs) into calcium alginate chitosan microcapsules using a gas-shearing technology. The MANDs can provide protection to MTX@HSA NPs with well-persisted biologic activity against gastric acid erosion and realize specific boost release of MTX@HSA NPs in the intestinal tract in response to the mild basic circumstance. The MTX@HSA NPs absorbed by intestine can selectively accumulate in inflammation lesion by exploiting the inflammation targeting ability of HSA. In the animal experiments, the MANDs show improved therapeutic efficacy for the treatment of both RA and colitis with minimized intestinal side effects in respect to the free MTX by oral administration. Therefore, this conceived oral MANDs can promote a more clinic popularity and enhanced benefits of MTX for the treatment of chronic inflammatory diseases.

KW - human serum albumin nanomedicines

KW - hydrogel microcapsules

KW - methotrexate

KW - oral administration

KW - rheumatoid arthritis

UR - https://www.scopus.com/pages/publications/85146310346

U2 - 10.1002/adfm.202211644

DO - 10.1002/adfm.202211644

M3 - Article

AN - SCOPUS:85146310346

SN - 1616-301X

VL - 33

JO - Advanced Functional Materials

JF - Advanced Functional Materials

IS - 9

M1 - 2211644

ER -

Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this